quantisnow
FeedTopReportsPricing
⌘K
Live feed
19:30:05·49d
INSIDERFiling
Beta Bionics Inc. logo

Chief Commercial Officer Hopman Mark sold $4,084 worth of shares (353 units at $11.57), decreasing direct ownership by 0.25% to 139,133 units (SEC Form 4)

BBNX· Beta Bionics Inc.
Health Care
Original source

Companies

  • BBNX
    Beta Bionics Inc.
    Health Care

Recent analyst ratings

  • Feb 9UpdateUBS$24.00
  • Jan 27UpdateTD Cowen$17.00
  • Jan 9UpdateBofA Securities-
  • Oct 21UpdateStifel$26.00
  • Oct 1UpdateGoldman$26.00
  • Jun 16UpdateTruist$26.00

Related

  • SEC2d
    SEC Form 10-Q filed by Beta Bionics Inc.
  • SEC2d
    Beta Bionics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR2d
    Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
  • SEC13d
    SEC Form DEFA14A filed by Beta Bionics Inc.
  • SEC13d
    SEC Form DEF 14A filed by Beta Bionics Inc.
  • PR23d
    Beta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care
  • PR24d
    Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Beta Bionics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022